Reduced Intensity Allograft in Chemosensitive Hodgkin Lymphoma (ReACH)
Research type
Research Study
Full title
Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET Positive Hodgkin Lymphoma (ReACH)
IRAS ID
6475
Contact name
Karl Peggs
Sponsor organisation
University College London
Eudract number
2008-004955-31
Clinicaltrials.gov Identifier
Research summary
Hodgkin lymphoma is a cancer of the lymphatic system and is treated with chemotherapy. A significant minority of patients will subsequently relapse and require further therapy. Many patients with relapsed Hodgkin??s Lymphoma can still achieve long term disease free survival with salvage treatment. Usual management includes salvage chemotherapy followed by autologous stem cell transplantation (autograft). However, patients with active disease (PET positivity) before autografting have a poorer outcome. Better disease control is likely to be achieved by allogeneic transplantation, but full conditioning regimes are very toxic and have a high mortality. Recently, reduced intensity conditioning (RIC) regimes have been used with much lower toxicity and encouraging disease free survival. This phase 2 study will determine disease free survival in a relatively poor prognosis group of Hodgkin??s lymphoma patients, using RIC transplantation.
REC name
London - London Bridge Research Ethics Committee
REC reference
09/H0804/73
Date of REC Opinion
14 Aug 2009
REC opinion
Further Information Favourable Opinion